STOCKHOLM, May 10, 2022
/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT,
Nasdaq Stockholm: CALTX) ("Calliditas") today
announced that its management team will
participate in the following upcoming investor conferences and
events:
- The 8th Annual LSX World Congress on
May 10-11, 2022 in London, United Kingdom
- The ABGSC Life Science Summit on May
18-19, 2022, in Stockholm,
Sweden.
- H.C. Wainwright Hybrid Global Investment Conference on
May 23-26, 2022.
- Jefferies Healthcare Conference on June 8-10, 2022 in New
York City, USA.
- Citi European Healthcare Conference on June 14-16, 2022 in London, United Kingdom
At the LSX World Congress, Calliditas Chief Executive Officer
Renée Aguiar-Lucander, Chief Financial Officer Fredrik Johansson and President of North America, Andrew
Udell will speak in three separate panel discussions focused
on global commercial strategy, IPO listings, and product launching,
respectively.
Panel discussion details:
Title: Challenges and Operational Scale Up For First Product
Launch
Speaker: Andrew Udell, President,
North America
Date: Tuesday, May 10, 2022,
11:20 GMT
Title: Go West! - Considerations
For US IPOs And Dual Listings
Speaker: Fredrik Johansson,
CFO
Date: Wednesday, May 11, 2022,
9:25 GMT
Title: Go-To-Market Strategies Across Geographies And Overall
Equity Returns
Speaker: Renee Aguiar-Lucander,
CEO
Date: Wednesday, May 11, 2022,
11:00 GMT
To register for the conference please click here.
Renee Aguiar-Lucander will
present at the ABGSC Life Science Summit on May 19th at 11:30am to 12pm CET.
Management will be presenting and will host one-on-one investor
meetings at the other three conferences. To schedule a one-on-one
meeting with Calliditas, please contact your representative at H.C
Wainwright, Jefferies, or Citi.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on May
10, 2022 at 8:30 a.m.
CET.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, TARPEYOTM (budesonide) delayed release
capsules, has been approved by the FDA and is the subject of a
marketing authorization application (MAA) with the European
Medicines Agency (EMA). Additionally, Calliditas is conducting a
pivotal clinical trial with its NOX inhibitor product candidate
setanaxib in primary biliary cholangitis and is initiating a head
and neck cancer Phase 2 trial with setanaxib. Calliditas' common
shares are listed on Nasdaq Stockholm (ticker: CALTX) and its
American Depositary Shares are listed on the Nasdaq Global Select
Market (ticker: CALT).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics-to-participate-in-upcoming-investor-conferences,c3563727
The following files are available for download:
|
https://mb.cision.com/Main/16574/3563727/1577208.pdf
|
Upcoming Conferences
Eng
|
View original
content:https://www.prnewswire.com/news-releases/calliditas-therapeutics-to-participate-in-upcoming-investor-conferences-301543433.html
SOURCE Calliditas Therapeutics